semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis (selected) years of age or older RA according to the 2010 Rheumatoid Arthritis Classification Joint symptoms for ≥ 3 months prior to screening DAS44 > 2.4 About to start DMARD therapy (methotrexate, salazopyrin, hydroxychloroquine, chloroquine, leflunomide) or increased dose of methotrexate by ≥10 mg weekly to a maximum dose of 25mg weekly (if already receiving >15mg will require add-on DMARD/anti-TNF or switch to alternative DMARD) add-on of alternative DMARD switch to alternative DMARD start of first anti-TNFα agent (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab)  (selected) Intra-articular steroid injection within 4 weeks prior to the baseline visit Prior treatment with anti-TNFα or other biological agent (rituximab, abatacept, tocilizumab) Malignancy within past 5 years (other than basal cell carcinoma that has been adequately treated or excised, squamous cell cancer of the skin, and cervical carcinoma in situ) History of Serious infection (defined as requiring parenteral antibiotics or hospitalization) within 3 months prior to the baseline visit Active tuberculosis or history of tuberculosis without documented curative treatment and/or positive tuberculin reaction to PPD (Purified Protein Derivative) For patients starting anti-TNF therapy, a positive TB screening test and no record of effective prophylaxis according to local expert recommendations Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Adenocarcinoma of the Gastroesophageal Junction Esophageal Cancer Gastric Cancer Patients must have unresectable advanced or metastatic histologically or cytologically confirmed adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJ) Patients must not have received treatment for metastatic or unresectable disease Patients must not have brain metastases Patients must have measurable and/or non-measurable disease Patients who have had HER-2 expression testing prior to patient consent to this study must be HER-2 negative; if HER-2 expression has not been tested prior to patient consent to this study, a second specimen must be submitted for HER-2 expression; if the specimen is HER-2 positive (or if HER-2 could not be evaluated), the patient will not be randomized Patients must have completed any prior neoadjuvant and adjuvant therapy for resectable disease at least 180 days prior to registration Zubrod performance status of 0-1 Hemoglobin ≥ 9 g/dL Absolute neutrophil count (ANC) ≥ 1,500/mcL Platelets ≥ 100,000/mcL
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Moderate to Severe Secondary Hyperparathyroidism Stage 5 Chronic Kidney Diseases A subject will only be included if all the following entry are met Patients ≥ 18 years of age Stage 5 chronic kidney disease (CKD) patients receiving hemodialysis and with moderate to severe secondary hyperparathyroidism (SHPT) Patients with anemia due to renal insufficiency but who are iron replete:; Transferrin saturation (TSAT) > 20% and Ferritin levels > 200 ng/mL and requiring treatment with erythropoietin (EPO) Patients with vitamin B levels > lower limit of normal (LLN) and folic acid levels > LLN Patients treated only with intravenous calcitriol for at least 6 months Patients with serum intact parathyroid hormone (iPTH) level > 500 pg/mL Patients with calcium phosphate product (Ca × PO4) < 65 mg²/dL² Patients willing to sign "written informed consents" before participating in any the study related activity Patients with phosphorus levels < 6.5 mg/dL and calcium levels < 11.2 mg/dL  A subject will be excluded from the study if he/she meets any of the following Patients who have known hypersensitivity and/or toxicity to vitamin D metabolites and/or to paricalcitol and/or to other product ingredients Patients who have participated in a clinical study within the last month Patients whose previous concomitant medication and laboratory data for 6 months prior to the baseline visit are not available Patients with known contraindication to selective Vitamin D receptor activators (VDRAs) according to the Summary of Product Characteristics (SmPC) Pregnancy, breast-feeding or planning a pregnancy within next 6 months after enrollment. Sexually active female patients not accepting appropriate contraceptive methods during the course of the study will also be excluded Hypertensive and diabetic patients who are not on an optimal and steady medication regimen for more than 30 days Patients with microcytic (mean corpuscular volume [MCV] < 80 fL) and macrocytic (MCV > 100 fL) anemia at screening that may be caused by diseases such as for microcytic anemias Iron Deficiency, Thalassemias, Anemia of Chronic Disease, Copper Deficiency, Zinc poisoning, Sideroblastic Anemia, macrocytic anemias -ethanol abuse, myelodysplastic syndromes, acute myeloid leukemias, reticulocytosis, drug induced anemia, liver disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Muscle Pain Joint Pain Age ≥ 18 years Women with a history of stage I-IIIa invasive breast cancer History of hormone-receptor positive cancer (either ER + or PR + or both) Are prescribed and are taking anastrozole, letrozole or exemestane for at least one month and have at least 7 months of AI treatment remaining Are experiencing AIMSS  Unable to read or understand English History of psychiatric disability affecting informed consent or compliance with drug intake Malabsorption syndrome or inability to take oral medication Has less than 7 months of AI therapy remaining
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 15.0-70.0,  Vitamin D Deficiency Vitamin D deficiency (< 25 nmol/l) Age 15 or above  Travel south of 45 degrees latitude during the trial Ongoing treatment with vitamin D supplementation Intake of light sensitive medicine, such as tetracyclins Skin light eruptions
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Vitamin D Metabolism is in Chronic Kidney Disease age 18-85 years; CKD stage III or V; serum 25(OH)D level ≤ 30ng/ml, and serum PTH levels > 70 pg/ml within the last 6 months, informed Consent  A history of liver disease, sarcoidosis, intestinal malabsorption requirement of dialysis during the study; serum calcium level >10.5 mg/dl calcium-phosphorus product > 70, or calcimimetics, or phosphorus binders; or medications that could affect vitamin D metabolism or history of parathyroidectomy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type II Diabetes Mellitus Laboratory test for HbA1c ≥ 8% within the past year Clinical diagnosis of DM Age > 18 years old Patient in a Beacon clinic Cell phone ownership or willingness to acquire a cell phone capable of receiving and sending SMS messages Women who are not pregnant  Failure to meet
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Scleroderma study group 1. patients with SSc 2. age years old and older 3. sign ICF control group healthy people
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Primary Hyperparathyroidism Confirmed hypercalcemic PHPT in postmenopausal women with serum calcium >10.2 mg/dL and < 12.0 mg/dL (nl: 8.6-10.2) T-score between -1.5 and -2.5 at any site. If the T-score is <-2.5, patients become candidates for parathyroid surgery. They will be enrolled only if they refuse the parathyroid surgery  hydroxyvitamin D level < 20 ng/ml Previous use of the bisphosphonate zoledronic acid (ever), alendronate or risedronate (within 12 months) or ibandronate (within 6 months) Current use of PTH, glucocorticoids, SERMS, estrogen (other than vaginal), calcitonin or pharmacological amounts of calcitriol Current or previous use of cinacalcet (within 6 months) Hyperthyroidism Rheumatoid arthritis or any other inflammatory joint disease Paget's disease of bone Malabsorption T-score <-3.5 at any site Signs of symptomatic PHPT (e.g, kidney stones within the past 5 years; fragility fracture within the past 2 years) Physical or mental handicapping condition that precludes ability to complete the protocol and/or provide informed consent
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Mucositis Patient has oral mucositis pain that is grade 3 or 4 according to the World Health Organization (WHO) Oral Mucositis Scale Patient has received at least one prior chemotherapy or radiation treatment Patient is at least 18 years old Patient or their legally authorized representative understands and voluntarily signs the written informed consent prior to any study-specific procedures. A copy of the signed informed consent form will be retained by the treating institution
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Coronary Artery Disease Endothelial Dysfunction Inflammation Male and nonpregnant females greater than 18 years of age ≥ 50% angiographic stenosis of at least 1 coronary artery or documented previous revascularization Serum 25-hydroxyvitamin D < 20 ng/ml  confinement to a nursing facility, institution or home GFR < 60 ml/min (by MDRD equation) presence of liver disease hypercalcemia NYHA class III or IV heart failure cardiogenic shock at time of presentation current planned or emergent CABG prior gastric or small bowel surgery pancreatitis malabsorption
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  X-linked Hypophosphatemia Satisfactory completion of KKP's sponsored KRN23-INT-001 clinical trial 2. eGFR ≥ 60 mL/min 3. Corrected Ca < 10.8 mg/dL 4. For female of child-bearing potential, a negative serum pregnancy test 5. A willingness to utilize adequate contraception and not become pregnant [or to have their partner(s) become pregnant] during the study 6. Additional apply  Subject experienced a safety-related event in the KRN23-INT-001 study 2. Pregnant or lactating female subject or pregnant or female planning to become pregnant during the study 3. Receipt of a live (attenuated) vaccine (except for influenza vaccines) during the course of the KRN23-INT-001 study and/or of this study 4. Condition which could present a concern for either the subject's safety or difficulty with data interpretation 5. Additional apply
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 3.0-40.0,  Asthma Vitamin D Resistant Rickets Vitamin D Resistent Rickets Age between 3 years  Any Chronic Lung Disease Febrile Illness in last 2 weeks Inhaled Corticosteroids over the past 2 weeks Bronchodilators over the past 24 hours Participation in any other clinical studies over the past 4 weeks
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Chronic Kidney Failure End-stage Renal Disease Disorders Associated With Peritoneal Dialysis Chronic peritoneal dialysis treatment(CPD) for at least the previous six months, Clinically stable Ages 30 to 65 years old Both genders Any racial or ethnic background Evidence that the subject is capable of giving informed consent and of adhering to the study protocol  No inflammatory or catabolic illnesses No hospitalizations within the previous three months except for vascular access revision No severe heart, liver or lung failure No cancer, other than basal cell carcinoma, systemic infections, vasculitis or other rheumatological diseases
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 13.0-45.0,  Vitamin D Deficiency African-Americans (blacks) 2. Age 13-45 3. Overweight/obese (BMI ≥ 85th percentile for their age and gender for age 13-17 and BMI ≥ 25 kg/m2 for age 18-45) 4. Relatively healthy (no medical history of any heart, lung, endocrine or malignant disorder) 5. Non pregnant 6. Not on any medication or vitamin supplements that can influence the study outcomes 7. Serum 25 hydroxy Vitamin D (25[OH] D) levels ≤ 20 ng/ml (50 nmol/L) at the time of screening  Not meeting any one or more of the above 2. Females who become pregnant/test positive on urine pregnancy test during the screening or any of the testing visits 3. Anyone who is taking any multivitamin supplements that contains vitamin D
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus Type 2 Men and women, ages ≥18 years Official diagnostic for type 2 diabetes fulfilled in patients on any type of oral or parenteral glucose-lowering treatment Independent living at home On stable regimen of BP meds (if any) with BP well controlled and/or K supplement (if any) for 2 months and which is deemed unlikely to change during the study Stable glucose control for 2 months by any approved method including insulin  Patients with type 1 diabetes (or insulin-requiring diabetes of unclear type) Patients on hemodialysis, with hyperparathyroidism or active cancer disease Patients with known metabolic bone disease Laboratory evidence of kidney (eGFR < 60 ml/min) or liver disease Dietary calcium intake exceeding 1500mg/d (as estimated by dietary history) OH) vitamin D levels at baseline > 70 nmol/L Calciuria (> 8 mmol/24 hours as measured by 24 hour urine collections) Hypo and hypercalcemias and hypo and hyperphosphatemias of any cause
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type II Over 18 years old Mentally competent Have diabetes or pre-diabetes or brought a family member who was diabetic/pre-diabetic (Diabetes: Fasting blood glucose higher than 125 mg/dl; Pre-diabetes: Fasting blood glucose between 100 and 124 mg/dl.)  They do not meet the above They are pregnant They have significant medical complications that prevent them from making changes to diet or level of physical activity
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  High Blood Cholesterol Adult patients with high cholesterol blood levels willing to participate in the study Patients must be on cholesterol lowering medications for three months with no dose change for six weeks  Patients not on cholesterol lowering medications or on medications for less than three months Any medication dose change in six weeks prior to their visit
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Renal Impairment For subjects with impaired renal function Subjects 18 to 75 years old with impaired renal function (MDRD formula between 15 and 89mL/min) medically stable since 3 months With body mass index (weight/height2) in the range 18 to 32 kg/m2 (inclusive) For healthy subjects Healthy subjects 18 to 75 years old with normal renal function (MDRD > 90 mL/min) and no proteinuria (<0.15g/L determined by urinalysis) matched with impaired renal function subjects on ethnic group, sex, age (+/ years), and BMI (+/  For impaired renal function subjects History of hepatic, cardiovascular (including conduction disturbance) or psychiatric disorder or any other condition which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of study results Evidence of liver disease Presence of concomitant pathology requiring intake of any drugs or substances known to be inhibitors or inductors of CYP enzymes Presence of metabolic or ionic disorders not controlled by adapted treatment Presence of significant anemia,nephrotic syndrome Renal transplantation For healthy subjects history of renal, cardiovascular, gastrointestinal, hepatic, neurological, endocrine or psychiatric disorders or any surgery which puts them at risk in the opinion of the investigator Any treatment within 14 days before or within 5 times the elimination half-life of that drug, whichever the longest, including treatment which could lead to inhibition or induction of CYP enzymes mainly CYP3A4 and CYP2D6 and with the exception of hormonal contraception and menopausal hormone replacement therapy